[go: up one dir, main page]

WO2010015652A3 - Thiazole compounds as medicaments for the treatment of (inter alia) cardiovascular diseases - Google Patents

Thiazole compounds as medicaments for the treatment of (inter alia) cardiovascular diseases Download PDF

Info

Publication number
WO2010015652A3
WO2010015652A3 PCT/EP2009/060145 EP2009060145W WO2010015652A3 WO 2010015652 A3 WO2010015652 A3 WO 2010015652A3 EP 2009060145 W EP2009060145 W EP 2009060145W WO 2010015652 A3 WO2010015652 A3 WO 2010015652A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
hydrogen
halo
alkoxy
medicaments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2009/060145
Other languages
French (fr)
Other versions
WO2010015652A2 (en
Inventor
Anne Marie Jeanne Bouillot
Nerina Dodic
Francoise Jeanne Gellibert
Olivier Mirguet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0814494A external-priority patent/GB0814494D0/en
Priority claimed from GB0818455A external-priority patent/GB0818455D0/en
Priority claimed from GB0818555A external-priority patent/GB0818555D0/en
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of WO2010015652A2 publication Critical patent/WO2010015652A2/en
Publication of WO2010015652A3 publication Critical patent/WO2010015652A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Disclosed are compounds of formula (I) wherein R1 and R2 are independently selected from hydrogen, halo, C1-4alkyl, C1-4alkoxy, CF3 and OCF3; -Y- represents formula (IA) R3 represents hydrogen, fluoro, chloro or C1-4alkyl; R4a and R4b each independently represent hydrogen, C1-4alkyl, C1-4alkoxy, CF3 or halo; and R5 represents a group Z-X; wherein Z is absent or represents (CH2)2 or O; and X represents formula (IB) wherein: J and L both represent CH, or one of J and L represents CH and the other represents N; when both J and L represent CH, R6 represents hydrogen, halo, CF3, C1-4alkyl or C1-4alkoxy in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, OCF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; or when one of J or L represents N, R6 represents hydrogen or halo in a meta or ortho position relative to the R7 substituent and R7 represents hydrogen, halo, CF3, C1-4alkyl, C1-4alkoxy, CH2OH, CN, CONR8R9 or CO2H; and R8 and R9 are independently selected from hydrogen and C1-4alkyl; or salts thereof which activate soluble guanylate cyclase (sGC), pharmaceutical compositions containing them, their use in medicine, and processes for their preparation.
PCT/EP2009/060145 2008-08-07 2009-08-05 Thiazole compounds as activators of soluble guanylate cyclase Ceased WO2010015652A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0814494A GB0814494D0 (en) 2008-08-07 2008-08-07 Compounds
GB0814494.1 2008-08-07
GB0818455.8 2008-10-08
GB0818455A GB0818455D0 (en) 2008-10-08 2008-10-08 Compounds
GB0818555A GB0818555D0 (en) 2008-10-09 2008-10-09 Compounds
GB0818555.5 2008-10-09

Publications (2)

Publication Number Publication Date
WO2010015652A2 WO2010015652A2 (en) 2010-02-11
WO2010015652A3 true WO2010015652A3 (en) 2010-05-14

Family

ID=41582171

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/060145 Ceased WO2010015652A2 (en) 2008-08-07 2009-08-05 Thiazole compounds as activators of soluble guanylate cyclase

Country Status (1)

Country Link
WO (1) WO2010015652A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2197551B1 (en) 2007-09-06 2016-12-28 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators
CA2720343A1 (en) 2008-04-04 2009-10-08 Takeda Pharmaceutical Company Limited Heterocyclic derivative and use thereof
JP5411300B2 (en) 2009-02-26 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション Soluble guanylate cyclase activator
WO2011130515A1 (en) * 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
GB2486631A (en) * 2010-12-01 2012-06-27 Univ Sheffield Phenol/quinone boronic acids/esters and method of preparation thereof
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
WO2013025425A1 (en) * 2011-08-12 2013-02-21 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
EP2594270A3 (en) 2011-11-18 2013-07-31 BIP Patents The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
DK2892891T3 (en) 2012-09-07 2019-10-14 Boehringer Ingelheim Int ALCOXYPYRAZOLES AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS
CN103304506B (en) * 2013-06-07 2015-05-20 陕西师范大学 Method for preparing fluorine-containing benzoxazole liquid crystal compound
EA032972B1 (en) 2014-07-22 2019-08-30 Бёрингер Ингельхайм Интернациональ Гмбх Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EP3525778A1 (en) 2016-10-11 2019-08-21 Bayer Pharma Aktiengesellschaft Combination containing sgc activators and mineralocorticoid receptor antagonists
WO2019081456A1 (en) 2017-10-24 2019-05-02 Bayer Aktiengesellschaft Use of activators and stimulators of sgc comprising a beta2 subunit
EP3498298A1 (en) 2017-12-15 2019-06-19 Bayer AG The use of sgc stimulators and sgc activators alone or in combination with pde5 inhibitors for the treatment of bone disorders including osteogenesis imperfecta (oi)
JP7314173B2 (en) 2018-04-30 2023-07-25 バイエル アクチェンゲゼルシャフト Use of sGC activators and sGC stimulants for the treatment of cognitive impairment
BR112020022340A2 (en) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamides replaced by 1,3-thiazol-2-yl for the treatment of diseases associated with nerve fiber sensitization
US11508483B2 (en) 2018-05-30 2022-11-22 Adverio Pharma Gmbh Method of identifying a subgroup of patients suffering from dcSSc which benefits from a treatment with sGC stimulators and sGC activators in a higher degree than a control group
EP3911675A1 (en) 2019-01-17 2021-11-24 Bayer Aktiengesellschaft Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
EP4011873A1 (en) 2020-12-10 2022-06-15 Bayer Aktiengesellschaft Substituted pyrazolo piperidine carboxylic acids
WO2023237577A1 (en) 2022-06-09 2023-12-14 Bayer Aktiengesellschaft Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288758A2 (en) * 1987-04-09 1988-11-02 Bayer Ag Dihydropyridinamides, process for their preparation and their use in medicines
WO1998049152A1 (en) * 1997-04-25 1998-11-05 Smithkline Beecham Corporation Protease inhibitors
WO2009071504A1 (en) * 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0288758A2 (en) * 1987-04-09 1988-11-02 Bayer Ag Dihydropyridinamides, process for their preparation and their use in medicines
WO1998049152A1 (en) * 1997-04-25 1998-11-05 Smithkline Beecham Corporation Protease inhibitors
WO2009071504A1 (en) * 2007-12-03 2009-06-11 Smithkline Beecham Corporation 2,6-disubstituted pyridines as soluble guanylate cyclase activators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9365574B2 (en) 2010-05-27 2016-06-14 Merck Sharp & Dohme Corp. Soluble guanylate cyclase activators

Also Published As

Publication number Publication date
WO2010015652A2 (en) 2010-02-11

Similar Documents

Publication Publication Date Title
WO2010015652A3 (en) Thiazole compounds as medicaments for the treatment of (inter alia) cardiovascular diseases
WO2008019967A3 (en) Phenyl, pyridine and quinoline derivatives
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
TW200833663A (en) Therapeutic agents
TW200833326A (en) Chemical compounds 572
WO2009080705A3 (en) Bis-thiazole derivatives, process for their preparation and their use as medicaments
NO20090172L (en) Substituted spirochetal derivative and its use as a drug for treating diabetes
WO2006048330A8 (en) 11βετα-hsd1 inhibitors
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
MX2010012390A (en) Phenyl or pyridinyl substituted indazoles derivatives.
MY141754A (en) Selected cgrp-antagonists, process for preparing them and their use as pharmaceutical compositions
MX2009005616A (en) Pyrido-pyrazine derivatives useful as herbicidal compounds.
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
WO2008081096A3 (en) Quinolinyl derivatives, method for preparing same, pharmaceutic compositions containing same, and use thereof as hypoglycemiant and hypolipemiant agents
WO2010094126A8 (en) Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ZA200809690B (en) Substituted in 5-phenylamino- 1, 3, 4-oxadiazol-2-ylcarbonylamino-4-phenoxycyclohexane carboxylic acid as inhibitors of acetyl coenzyme a diacylglycerol acyltransferase
UA94606C2 (en) 2-thioxanthine derivatives, composition containing the compound and the use thereof in therapy
MY145613A (en) Novel compounds
WO2004031160A3 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
WO2007129066A8 (en) 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
WO2009020137A1 (en) Aminopyrazole amide derivative
WO2006077025A3 (en) Morpholines as 5ht2c agonists
MX2007004740A (en) 2-amido-4-phenylthiazole derivatives, the preparation and the therapeutic use thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09781510

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09781510

Country of ref document: EP

Kind code of ref document: A2